Rate My Professor Peter Foley

Peter Foley's research specializations center on psoriasis, atopic dermatitis, non-melanoma skin cancers, clinical trials, basal cell carcinoma, squamous cell carcinoma, phototherapy, and photodynamic therapy. He has acted as principal investigator in over 160 clinical trials, including pivotal studies for dupilumab, tralokinumab, lebrikizumab, nemolizumab, amlitelimab, rocatinlimab, baricitinib, upadacitinib, and abrocitinib in atopic dermatitis. His publication record exceeds 160 manuscripts, garnering over 11,800 citations. Key publications include 'Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative,' 'Atopic dermatitis in adults: An Australian management consensus,' 'Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting,' 'Building the foundations for an international patient-centred outcomes set for psoriasis: A scoping study' (2026), 'Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis' (2026), and 'Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review' (2026). Foley demonstrates significant influence through leadership roles: Australia's sole councillor on the International Psoriasis Council, founding member of the Australasian Psoriasis Collaboration, co-convener of the Australasian Dermatology Registry, chair of the steering committee for the Pillars of Dermatology Practice Symposium, and participant in the treat-to-target project for atopic dermatitis.